RxDoctor Payments Data

Aimee Colegrove

Family · Williamson, WVNPI 1245666817

Payments from drug & device makers

$575in general payments, 2019–2025

Across 30 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$412
  • GSK$70
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$21
  • Boehringer Ingelheim$16
  • Novo Nordisk$16
  • Amgen$14
  • plus $27 from 2 others

What the payments were for

  • Food & beverage$575100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$575 in reported general payments places this provider in the 55th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$19,197
Medicare patients
58
Services billed
424

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$88,650
MounjaroTirzepatide64$87,881
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$79,448
FarxigaDapagliflozin Propanediol74$78,193
EliquisApixaban53$61,072
JardianceEmpagliflozin49$51,404
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$36,294
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$15,949
Albuterol Sulfate HfaAlbuterol Sulfate163$7,119
LinzessLinaclotide11$5,963
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$5,570
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$3,663
Dexlansoprazole DrDexlansoprazole15$3,594
Novolog FlexpenInsulin Aspart12$3,089
Insulin Lispro Kwikpen U-100Insulin Lispro20$3,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga$412$157,641149 claims
Novo NordiskOzempic$16$88,65069 claims
PfizerEliquis, Paxlovid$14$62,50168 claims
Boehringer IngelheimJardiance$16$51,40449 claims
GSKTrelegy Ellipta$70$36,29442 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,507 family providers in West Virginia.

Other family in Williamson

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →